The Influence of Parental Marijuana Use on Children
Data suggest that the ascendancy of medicalization, legalization, and social acceptability of...
Read More
Author: Janine Anthes
The Influence of Parental Marijuana Use on Children
Data suggest that the ascendancy of medicalization, legalization, and social acceptability of...
Read MorePart II: Avoiding Liability in Telemedicine: HIPAA & Informed Consent
That you are a responsible covered entity under HIPAA and a fiduciary for the privacy of your patients’ PHI do not decrease with telemedicine. In fact, it is a setting in which you want to be very careful, particularly if...
Read More
Masitinib Impresses in Progressive MS
Perspectives from Patrick Vermersch, MD, Professor of Neurology at Lille University in France, and...
Read More
Subclinical Vascular Damage Scoring Failing HIV Patients
Data indicate that people living with HIV (PLWHIV) have an increased risk of cardiovascular...
Read MoreACTRIMS-ECTRIMS: Phase 3 EXCHANGE, Insights From Lead Investigator
The interim analysis of the EXCHANGE trial suggest that, for patients with relapsing multiple sclerosis, immediate conversion from oral/injectable disease modifying therapies to siponimod without any washout period (within 24...
Read MoreECTRIMS 2020 Encore Event: NG-Specific Biomarkers Can Quickly Differentiate NMOSD from MS
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreECTRIMS 2020 Encore Event: Interrupting DMT Due to Pregnancy Increases NfL Levels in MS
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read MoreECTRIMS 2020 Encore Event: Brain Alterations at Onset of First Demyelinating Event
Neurite orientation dispersion and density imaging (NODDI) can detect brain microstructural and metabolic alterations after the first demyelinating event in MS [1]. There was increased axonal dispersion in normal-appearing white...
Read MoreECTRIMS 2020 Encore Event: EDSS and Age Are Risk Factors for Severe COVID-19 in MS Patients
In an observational French cohort study, Expanded Disability Status Scale (EDSS) and age were found to be independent risk factors of severe COVID-19, while exposure to immunomodulating disease-modifying treatment (DMT;...
Read MoreECTRIMS 2020 Encore Event: MS Patients Have No Increased Risk of Contracting COVID-19
People with MS are not more susceptible to COVID-19 infection than the UK general population, suggest results of the largest community-based study of COVID-19 in people with MS worldwide [1]. During lockdown, with strict...
Read MoreFunctional Potential of Gut Microbiome in Pediatric MS
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreGold Nanocrystals May Improve Brain Metabolic Profile
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreEculizumab Reduces Long-Term Relapse Risk in AQP4+ NMOSD
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Read MoreGender-based Approach to MS Therapeutics: A Missed Opportunity
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...
Read MoreMasitinib Possible New Treatment of Progressive MS
Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...
Read MorePredictive Value of Neurodegenerative CSF Markers in MS
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreAmantadine, modafinil, and methylphenidate for MS-related fatigue
For one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...
Read MoreManagement of PPMS and SPMS with approved DMT
In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read More
No New Safety Signals in Ofatumumab Open-Label Data
Only a few weeks prior to MSVirtual2020, the fully human anti-CD20 monoclonal antibody ofatumumab...
Read More